1.
Gastric cancer
by Van Cutsem, Eric, Prof
The Lancet (British edition), 2016, Vol.388 (10060), p.2654-2664
2.
Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gas...
by Doi, Toshihiko
The lancet oncology, 2017, Vol.18 (11), p.1512-1522
3.
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial
by Shapiro, Joel, Dr
The lancet oncology, 2015, Vol.16 (9), p.1090-1098
4.
Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with...
by Al-Batran, Salah-Eddin, Prof
The lancet oncology, 2016, Vol.17 (12), p.1697-1708
5.
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-bl...
by Wilke, Hansjochen, Prof
The lancet oncology, 2014, Vol.15 (11), p.1224-1235
6.
Oesophageal carcinoma
by Pennathur, Arjun, MD
The Lancet (British edition), 2013, Vol.381 (9864), p.400-412
7.
Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, dou...
by Catenacci, Daniel V T
The lancet oncology, 2017, Vol.18 (11), p.1467-1482
8.
Guidelines for the management of oesophageal and gastric cancer
by Allum, William H
Gut, 2011, Vol.60 (11), p.1449-2
9.
Oesophageal cancer
by Lagergren, Jesper
The Lancet (British edition), 2017, Vol.390 (10110), p.2383-2396
10.
First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial
by Janjigian, Yelena Y
The lancet oncology, 2020, Vol.21 (6), p.821-831
11.
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phas...
by Waddell, Tom, MBBCh
The lancet oncology, 2013, Vol.14 (6), p.481-489
12.
Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study
by Noordman, Bo Jan
The lancet oncology, 2018, Vol.19 (7), p.965-974
13.
Prognostic Significance of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Oncologic Outcomes of Esophageal Cancer: A Systematic Review and Meta-analysis
by Yodying, Hariruk
Annals of surgical oncology, 2015, Vol.23 (2), p.646-654
14.
Global incidence of oesophageal cancer by histological subtype in 2012
by Arnold, Melina
Gut, 2015, Vol.64 (3), p.381-387
15.
7th Edition of the AJCC Cancer Staging Manual: Esophagus and Esophagogastric Junction
by Rice, Thomas W
Annals of surgical oncology, 2010, Vol.17 (7), p.1721-1724
16.
Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, o...
by Cunningham, David, Prof
The lancet oncology, 2017, Vol.18 (3), p.357-370
17.
Prognostic Significance of Sarcopenia in Patients with Esophagogastric Junction Cancer or Upper Gastric Cancer
by Kudou, Kensuke
Annals of surgical oncology, 2017, Vol.24 (7), p.1804-1810
18.
Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck sq...
by Melichar, Bohuslav, Prof
The lancet oncology, 2015, Vol.16 (4), p.395-405
19.
Elevated Preoperative Neutrophil:Lymphocyte Ratio as a Predictor of Postoperative Disease Recurrence in Esophageal Cancer
by Sharaiha, Reem Z
Annals of surgical oncology, 2011, Vol.18 (12), p.3362-3369
20.
Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial
by Crosby, Thomas, FRCR
The lancet oncology, 2013, Vol.14 (7), p.627-637
